Fibrosing cholestatic hepatitis following cytotoxic chemotherapy for small-cell lung cancer.
Fibrosing cholestatic hepatitis (FCH) is a variant of viral hepatitis reported in hepatitis B virus or hepatitis C virus infected liver, renal or bone transplantation recipients and in leukemia and lymphoma patients after conventional cytotoxic chemotherapy. FCH constitutes a well-described form of fulminant hepatitis having extensive fibrosis and severe cholestasis as its most characteristic pathological findings. Here, we report a case of a 49-year-old patient diagnosed with small-cell lung cancer who developed this condition following conventional chemotherapy-induced immunosuppression. This is the first reported case in the literature of FCH after conventional chemotherapy for a solid tumor. In addition to a detailed report of the case, a physiopathological examination of this potentially life-threatening condition and its treatment options are discussed.
Ceballos-Viro
Jaime
J
Department of Oncology, Clínica Universidad de Navarra, c/Pío XII 36, 31008 Pamplona (Navarra), Spain.
López-Picazo
José-M
JM
Pérez-Gracia
José-L
JL
Sola
Jesús-J
JJ
Aisa
Gregorio
G
Gil-Bazo
Ignacio
I
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D002780:Cholestasis, Intrahepatic / Q000209:etiology* / Q000473:pathology; D017809:Fatal Outcome; D005355:Fibrosis / Q000209:etiology* / Q000473:pathology; D016174:Hepacivirus; D006515:Hepatitis B virus; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D055752:Small Cell Lung Carcinoma / Q000188:drug therapy* / Q000473:pathology
D000970:Antineoplastic Agents; D007166:Immunosuppressive Agents